Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6093261 | 0.99 | BRD4 (0.44) | BRD4SGMS2METGSK3BLRRK2 | |
| SCHEMBL6094134 | 0.98 | BRD4 (0.43) | BRD4SGMS2METGSK3BLRRK2 | |
| SCHEMBL6093719 | 0.92 | SGMS2 (0.37) | BRD4SGMS2GSK3BLRRK2IRAK4 | |
| Hydrochloric Acid SCHEMBL6094797 | 0.91 | SGMS2 (0.36) | BRD4SGMS2GSK3BLRRK2IRAK4 | |
| SCHEMBL6092102 | 0.90 | SGMS2 (0.37) | SGMS2GSK3BLRRK2IRAK4 | |
| Hydrochloric Acid SCHEMBL6093849 | 0.89 | SGMS2 (0.36) | SGMS2GSK3BLRRK2IRAK4 | |
| SCHEMBL7392263 | 0.86 | GSK3B (0.46) | GSK3BMEN1KMT2A | |
| SCHEMBL6095966 | 0.84 | BUB1 (0.40) | MEN1KMT2A | |
| SCHEMBL8258291 | 0.83 | HTR2C (0.46) | BRD4SGMS2METLRRK2 | |
| Hydrochloric Acid SCHEMBL6092747 | 0.83 | BUB1 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | claimed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | claimed |
| EP-1210328-A1 | FUSED PYRROLECARBOXAMIDES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-06-05 | — | — | EP | claimed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | claimed |
| WO-2001016103-A1 | FUSED PYRROLECARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2001-03-08 | — | — | WO | claimed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-6515140-B2 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators; drug abruse | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | disclosed |
| US-6211365-B1 | BRAIN DISORDERS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | BRD4 1812/4885SGMS2 4603/4885MET 4295/4885 |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | BRD4 1713/4885SGMS2 4573/4885MET 3730/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | BRD4 1790/4885SGMS2 4628/4885MET 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.